Report Ocean has published a new report on the Narcolepsy Therapeutics Market, delivering an extensive analysis of key factors such as market restraints, drivers, and opportunities. The report offers ...

The European Commission's Antitrust unit cleared Friday the acquisition of US-based pharmaceutical company Cephalon Inc. (CEPH) by the generic pharmaceutical company Teva Pharmaceuticals ...

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Cephalon Inc. (NASDAQ: CEPH) announced today that they received approval from the European Commission to proceed with Teva’s acquisition of ...

Support OpenSecrets during our NewsMatch campaign and double your donation! Help keep our resources and data free for the general public.

You are one of 7.5 million annual visitors to OpenSecrets. If you each donated just $1 a year, we'd never worry about funding again.

Former CFO of Cephalon Inc. and Philips Electronics North America will lead worldwide finance activities for growth oriented global oncology company Novocure Ltd., a commercial stage, private oncology ...

The European Union has fined Teva and its neurology unit Cephalon €60.5 million for an elaborate “pay for delay” scheme that prevented cheaper generic competition for its sleep disorder drug ...

The case arose from Cephalon’s acquisition of Ception Therapeutics, which had begun developing an antibody called RSZ that showed promise in treating eosinophilic asthma (“EA”) and ...

It is not Teva's first EU fine. EU regulators in 2020 fined the company and drug-maker Cephalon -- which Teva later bought -- for colluding to delay a cheaper generic version of a sleep disorder drug.

This is not the first time Teva has received a fine in the EU. In 2020, the pharmaceutical group and its former rival Cephalon were jointly fined €60.5mn for conspiring to fix the price of sleep ...